Humanigen, Inc. (@humanigen) header
Humanigen, Inc. (@humanigen) profile picture

Humanigen, Inc.

@humanigen

Humaneered® Monoclonal Antibodies to Neutralize Cytokine Storm Induced by SARS-CoV-2 (COVID-19), CAR-T, and GvHD. https://teapaw.org/t.co/slsnc93hH3…

 Short Hills, NJ
humanigen.com
Joined November 2018
  • Tweets443
  • Following92
  • Followers2.9K
59Media
Photo by Humanigen, Inc. (@humanigen)Photo by Humanigen, Inc. (@humanigen)Photo by Humanigen, Inc. (@humanigen)Photo by Humanigen, Inc. (@humanigen)Photo by Humanigen, Inc. (@humanigen)Photo by Humanigen, Inc. (@humanigen)Photo by Humanigen, Inc. (@humanigen)Photo by Humanigen, Inc. (@humanigen)Photo by Humanigen, Inc. (@humanigen)Photo by Humanigen, Inc. (@humanigen)
Humanigen Presents Promising New Hematologic Data from PREACH-M Trial for Chronic Myelomonocytic Leukemia Treatment at the 2023 European Hematology Association Congress Full Story: nfne.ws/169164 @humanigen $HGEN #HGEN #Humanigen #Chemicals #Pharmaceutical #Medical
Humanigen Presents Promising New Hematologic Data from PREACH-M Trial for Chronic Myelomonocytic...

Humanigen Presents Promising New Hematologic Data from PREACH-M Trial for Chronic Myelomonocytic...

Of the 14 participants enrolled and treated with lenzilumab plus azacitidine, ten are evaluable with three to eighteen months of...

newsfilecorp.com
13
10
1
22
7,866
Humanigen was honored to present progress from the PREACH-M trial evaluating lenzilumab in CMML today at AACR in Orlando, FL #HGEN
Image from Humanigen, Inc. (@humanigen)
6
20
26
8,394
Humanigen - Lenzilumab Being Studied as a Potential First Treatment in Thirty Years with a Novel Mechanism of Action for Chronic Myelomonocytic Leukemia (CMML), an Orphan Form of Leukemia Full Story: newsfilecorp.com/release/162… @humanigen $HGEN #HGEN #Humanigen
Humanigen - Lenzilumab Being Studied as a Potential First Treatment in Thirty Years with a Novel...

Humanigen - Lenzilumab Being Studied as a Potential First Treatment in Thirty Years with a Novel...

CMML is an aggressive, poorly understood cancer; approximately 20% of patients survive three years from diagnosisEleven subjects dosed with lenzilumab...

newsfilecorp.com
6
7
3
36
5,688
Humanigen Reports Third Quarter 2022 Financial Results Full Story: bit.ly/3E7cE9x @humanigen $HGEN #HGEN #Humanigen #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #Earnings #QuarterlyResults #Results #NASDAQ #Investing
11
2
7
Humanigen Announces Participation and Presentation at Jefferies London Healthcare Conference Full Story: bit.ly/3EknbPT @humanigen $HGEN #HGEN #Humanigen #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #NASDAQ #Investing
2
3
11
Humanigen Announces Retention of SC&H Capital as Financial Advisor Full Story: bit.ly/3sIxK8K @humanigen $HGEN #HGEN #Humanigen #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #NASDAQ #Investing
3
1
12
Humanigen and SAHMRI Announce Expansion of the PREACH-M Study of Lenzilumab in CMML Full Story: bit.ly/3DlNtRM @humanigen $HGEN #HGEN #Humanigen #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #NASDAQ #Investing
14
1
2
18
Humanigen to Participate in H.C. Wainwright and Cantor Investor Conferences in September 2022 Full Story: bit.ly/3BjcImf @humanigen $HGEN #HGEN #Humanigen #Chemicals #Pharmaceutical #Biotechnology #Medical #Pharmaceuticals #NASDAQ #Investing
15
1
1
16
Humanigen Implements Strategic Realignment of Pipeline and Resources to Achieve Key Clinical Milestones Full Story: bit.ly/3ottaJp @humanigen $HGEN #HGEN #Humanigen #Chemicals #Pharmaceutical #Pharmaceuticals #Biotechnology #Medical #NASDAQ #Investing
13
2
1
26
Humanigen is pleased to announce peer-reviewed publication in Thorax supporting early treatment of hospitalized COVID-19 patients with lenzilumab guided by C-Reactive Protein (CRP) thorax.bmj.com/content/early…
23
16
6
66
A press release with some additional detail is also available on our investor relations website ir.humanigen.com/English/new…
2
19
NIH/NIAID Locks ACTIV-5/BET-B Database HGEN received notice today from the National Institute of Allergy and Infectious Diseases (NIAID) that they have completed database lock for the Big Effect Trial of lenzilumab ir.humanigen.com/English/new…
10
11
5
67
Watch HGEN Annual Meeting at 1pm EDT today. Access the meeting in listen-only mode via the Guest tab. central.virtualshareholderme…
6
7
1
26
Humanigen, Inc. retweeted
Tom Wenseleers (@TWenseleers) profile picture
Tom Wenseleers@TWenseleers25 Apr 2022
It's as if medicine agencies still haven't come to terms with the fact that SARS-CoV2 evolves ca 2.5x faster than the fastest evolving influenza strain. And that vaccine updates would have to be made twice as fast then as for influenza... teapaw.org/trvrb/status/151187159…
Trevor Bedford (@trvrb) profile pictureTrevor Bedford
@trvrb7 Apr 2022
Replying to @trvrb
My main point was really how fast evolution has been proceeding. We see that SARS-CoV-2 variants have (1) displaced existing genetic diversity and (2) accumulated amino acid changes in the relevant domain much faster than seen in the fastest seasonal flu subtype H3N2. 2/13
Image from Trevor Bedford (@trvrb)
8
178
9
519
The ability of the virus to mutate, in a manner that confers the potential for immune escape, highlights the importance of treatments that target the host's immune response rather than the virus itself. #variantagnostic
Tom Wenseleers (@TWenseleers) profile pictureTom Wenseleers@TWenseleers25 Apr 2022
Replying to @TWenseleers
The growth rate advantage of BA.4 & BA.5 over BA.2 is similar than that of BA.2 over BA.1 and of Delta over Alpha. But with caveat that BA.4 & BA.5 carry 2 mutations in the spike receptor binding domain that are predicted to confer some immune escape. teapaw.org/jbloom_lab/status/1513…
6
7
3
54
We believe that COVID-19 will become a serious endemic disease and will continue to impact society, healthcare systems and patients for years to come.
Tom Wenseleers (@TWenseleers) profile pictureTom Wenseleers@TWenseleers25 Apr 2022
The BA.4 & BA.5 Omicron subvariant-driven increase of new confirmed Covid cases in South Africa gives a good idea of what the endemic equilibrium will look like: a significant wave every 6 months with significant mortality & morbidity. 🧵
Image from Tom Wenseleers (@TWenseleers)
4
4
43
FDA halts the use of GSK's Covid-19 drug completely as BA.2 subvariant blankets the country – Endpoints News. Time for a variant agnostic mAB? #lenzilumab endpts.com/fda-halts-the-use…
FDA halts the use of GSK's Covid-19 drug completely as BA.2 subvariant blankets the country

FDA halts the use of GSK's Covid-19 drug completely as BA.2 subvariant blankets the country

It only took the Omicron BA.2 subvariant three business days to go from shutting down GlaxoSmithKline and Vir Biotechnology's Covid-19 treatment sotrovimab in 22 states, as of last Friday, to ...

endpoints.news
21
11
3
78
Humanigen, Inc. retweeted
P1 /human (@stolgic) profile picture
P1 /human
@stolgic5 Apr 2022
$HGEN New LIVE-AIR commentary published in ACP journals acpjournals.org/doi/10.7326/…
Image from P1 /human (@stolgic)
3
16
84
Watch the latest investor presentation from Lytham Partners Spring 2022 Investor Conference available starting at 11am EDT today wsw.com/webcast/lytham4/regi…
20
9
2
66
Humanigen, Inc. retweeted
Kyle Hunter (@benitoitekid) profile picture
Kyle Hunter@benitoitekid25 Mar 2022
$hgen is mentioned in this article posted by Reuters… Cameron was one of the 5….. More big progress. I’d love to see them tweet about this on @humanigen reuters.com/business/healthc…
Insight: Drugmakers, scientists begin the hunt for long COVID treatments

Insight: Drugmakers, scientists begin the hunt for long COVID treatments

After producing vaccines and treatments for acute COVID-19 in record time, researchers and drugmakers are turning to finding a cure for long COVID, a more elusive target marked by hundreds of...

reuters.com
1
8
41
Load more